PMID- 36142760
OWN - NLM
STAT- MEDLINE
DCOM- 20220926
LR  - 20230301
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 18
DP  - 2022 Sep 16
TI  - Peroxisome Proliferator-Activated Receptor-alpha (PPARalpha) Expression in a Clinical 
      Population of Pakistani Patients with Type 2 Diabetes and Dyslipidemia.
LID - 10.3390/ijms231810847 [doi]
LID - 10847
AB  - Poor glycemic control and dyslipidemia are hallmarks of type 2 diabetes mellitus 
      (T2DM), which predispose to cardiovascular diseases. Peroxisome 
      proliferator-activated receptor-alpha (PPARalpha) has been associated with 
      atherosclerosis, but its role in T2DM is less clear. Previously, we studied PPARalpha 
      expression levels in diabetics with and without dyslipidemia (DD). In this study 
      we described the association with fasting blood glucose, HbA1c levels and lipid 
      levels of the study population. Patient demography and biochemical data were 
      collected from hospitals in Islamabad, Pakistan, and RT-PCR data of PPARalpha 
      expression were retrieved from our previous study from the same cohort. We 
      performed t-tests and regression analysis to evaluate the relationships between 
      PPARalpha expression and demographic and clinical variables. As expected, body mass 
      index and HbA1c were elevated in T2DM and DD patients compared to controls. Blood 
      lipids (total cholesterol, triglycerides, LDL and HDL) were significantly higher 
      in the DD group compared to the other two groups. In the T2DM and DD groups, the 
      PPARalpha expression was not associated with any of the physical and biochemical 
      parameters measured in this study. Expression of the PPARalpha gene was independent 
      of blood lipids and glycemic control in this study. Further research is necessary 
      to better understand the biological parameters of PPARalpha expression.
FAU - Arif, Maria
AU  - Arif M
AD  - Department of Biochemistry and Molecular Biology, Army Medical College, National 
      University of Medical Sciences, Rawalpindi 46000, Punjab, Pakistan.
FAU - Mondal, Tanmoy
AU  - Mondal T
AD  - Department of Biology, Howard University, Washington, DC 20059, USA.
FAU - Majeed, Asifa
AU  - Majeed A
AUID- ORCID: 0000-0002-3972-719X
AD  - Department of Biochemistry and Molecular Biology, Army Medical College, National 
      University of Medical Sciences, Rawalpindi 46000, Punjab, Pakistan.
FAU - Loffredo, Christopher A
AU  - Loffredo CA
AD  - Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown 
      University, Washington, DC 20057, USA.
FAU - Korba, Brent E
AU  - Korba BE
AD  - Department of Microbiology & Immunology, Georgetown University, Washington, DC 
      20057, USA.
FAU - Ghosh, Somiranjan
AU  - Ghosh S
AUID- ORCID: 0000-0002-5280-7418
AD  - Department of Biology, Howard University, Washington, DC 20059, USA.
LA  - eng
GR  - U54 MD007597/MD/NIMHD NIH HHS/United States
GR  - 9141/National University of Medical Sciences/
GR  - U54 MD007597-31-5959/NH/NIH HHS/United States
PT  - Journal Article
DEP - 20220916
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Lipids)
RN  - 0 (PPAR alpha)
RN  - 0 (Triglycerides)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Blood Glucose/metabolism
MH  - Cholesterol
MH  - *Diabetes Mellitus, Type 2/complications/genetics
MH  - *Dyslipidemias/genetics
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Lipids
MH  - PPAR alpha/genetics/metabolism
MH  - Pakistan
MH  - Triglycerides
PMC - PMC9505490
OTO - NOTNLM
OT  - PPARalpha gene
OT  - diabetic dyslipidemia
OT  - serum lipid profile
OT  - type 2 diabetes
COIS- The authors declare no conflict of interest.
EDAT- 2022/09/24 06:00
MHDA- 2022/09/28 06:00
PMCR- 2022/09/16
CRDT- 2022/09/23 01:26
PHST- 2022/07/30 00:00 [received]
PHST- 2022/08/26 00:00 [revised]
PHST- 2022/09/02 00:00 [accepted]
PHST- 2022/09/23 01:26 [entrez]
PHST- 2022/09/24 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2022/09/16 00:00 [pmc-release]
AID - ijms231810847 [pii]
AID - ijms-23-10847 [pii]
AID - 10.3390/ijms231810847 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Sep 16;23(18):10847. doi: 10.3390/ijms231810847.